Cargando…

Applying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: a Latin American perspective

OBJECTIVE: To evaluate the performance of the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) criteria in terms of earlier patients’ classification in comparison to the 1982/1997 ACR or the 2012 Systemic Lupus International Co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pons-Estel, Guillermo J, Ugarte-Gil, Manuel Francisco, Harvey, Guillermina B, Wojdyla, Daniel, Quintana, Rosana, Saurit, Verónica, Soriano, Enrique R, Bonfa, Eloisa, Massardo, Loreto, Cardiel, Mario, Vila, Luis M, Griffin, Russell, Pons-Estel, Bernardo A, Alarcón, Graciela S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Lupus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999682/ https://www.ncbi.nlm.nih.gov/pubmed/31958284 http://dx.doi.org/10.1136/rmdopen-2019-001097

Ejemplares similares

Predictors of renal damage in systemic lupus erythematous patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL)
por: Reátegui-Sokolova, Cristina, et al.
Publicado: (2020)

Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2019)

Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in an academic tertiary care centre
por: Schmidtmann, Irene, et al.
Publicado: (2023)

Performance of the proposed ACR–EULAR classification criteria for systemic lupus erythematosus (SLE) in a cohort of patients with SLE with neuropsychiatric symptoms
por: Gegenava, Maka, et al.
Publicado: (2019)

Global excellence in rheumatology in Latin America: The case of systemic lupus erythematosus
por: Ugarte-Gil, Manuel F., et al.
Publicado: (2023)

Performance of the 2019 EULAR/ACR systemic lupus erythematosus classification criteria in a cohort of patients with biopsy-confirmed lupus nephritis
por: Wang, Huijing, et al.
Publicado: (2021)

Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations
por: Kostopoulou, Myrto, et al.
Publicado: (2020)

Disease features and outcomes among US lupus patients of Hispanic origin and their Mestizo counterpart in Latina America
por: Ugarte-Gil, Manuel, et al.
Publicado: (2014)

Jaccoud’s arthropathy in SLE: findings from a Latin American multiethnic population
por: Quintana, Rosana, et al.
Publicado: (2019)

Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and disease-related risk factors reported by the EULAR recommendations
por: Drosos, George C, et al.
Publicado: (2023)

Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis?
por: Ugolini-Lopes, Michelle R, et al.
Publicado: (2017)

Performance of the 2017 EULAR/ACR criteria for idiopathic inflammatory myopathies in a cohort of patients from Latin America
por: Valenzuela, Antonia, et al.
Publicado: (2022)

Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2021)

Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies
por: Holmqvist, Marie, et al.
Publicado: (2015)

Role of P-glycoprotein on CD69(+)CD4(+) cells in the pathogenesis of proliferative lupus nephritis and non-responsiveness to immunosuppressive therapy
por: Tsujimura, Shizuyo, et al.
Publicado: (2017)

Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus
por: Tydén, Helena, et al.
Publicado: (2017)

Environmental and lifestyle factors influencing risk of congenital heart block during pregnancy in anti-Ro/SSA-positive women
por: Meisgen, Sabrina, et al.
Publicado: (2017)

Systemic lupus erythematosus: state of the art on clinical practice guidelines
por: Tamirou, Farah, et al.
Publicado: (2019)

Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience
por: Tani, Chiara, et al.
Publicado: (2019)

Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases
por: Flint, Shaun M, et al.
Publicado: (2016)

Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2020)

The impact of upper limb exercise on function, daily activities and quality of life in systemic lupus erythematosus: a pilot randomised controlled trial
por: Keramiotou, Kyriaki, et al.
Publicado: (2020)

Escaping the catch 22 of lupus anticoagulant testing
por: Vinholt, Pernille Just, et al.
Publicado: (2020)

Impact of fatigue on health-related quality of life and illness perception in a monocentric cohort of patients with systemic lupus erythematosus
por: Elefante, Elena, et al.
Publicado: (2020)

Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis
por: Yazdany, Jinoos, et al.
Publicado: (2020)

Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment
por: Davies, Jennifer C, et al.
Publicado: (2020)

Preclinical to clinical translation of cenerimod, a novel S1P(1) receptor modulator, in systemic lupus erythematosus
por: Strasser, Daniel S, et al.
Publicado: (2020)

Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy
por: Baker, Matthew, et al.
Publicado: (2020)

High p16(INK4a), a marker of cellular senescence, is associated with renal injury, impairment and outcome in lupus nephritis
por: Tilman, Gaëlle, et al.
Publicado: (2021)

White matter hyperintensities associate with cognitive slowing in patients with systemic lupus erythematosus and neuropsychiatric symptoms
por: Monahan, Rory Caitlin, et al.
Publicado: (2021)

Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
por: Assawasaksakul, Theerada, et al.
Publicado: (2021)

Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years
por: Zhang, Fengchun, et al.
Publicado: (2022)

Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations
por: Monahan, Rory C, et al.
Publicado: (2022)

Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Validation of a machine learning approach to estimate Systemic Lupus Erythematosus Disease Activity Index score categories and application in a real-world dataset
por: Alves, Pedro, et al.
Publicado: (2021)

Circulating mitochondrial DNA copy numbers represent a sensitive marker for diagnosis and monitoring of disease activity in systemic lupus erythematosus
por: Giaglis, Stavros, et al.
Publicado: (2021)

Dissecting signalling pathways associated with intrarenal synthesis of complement components in lupus nephritis
por: Tampe, Desiree, et al.
Publicado: (2022)

Fatigue is independently associated with disease activity assessed using the Physician Global Assessment but not the SLEDAI in patients with systemic lupus erythematosus
por: Mertz, Philippe, et al.
Publicado: (2022)

Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial
por: Wang, Huijing, et al.
Publicado: (2022)

Worse long-term renal outcome of lupus nephritis patients of African descent living in Europe
por: Enfrein, Antoine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7bdr8okq7cdlmlm8c545dndscf